New SRNA Resources for Understanding NMOSD Treatment Options

With the FDA approval of three medications (Soliris, Uplizna, and Enspryng) for maintenance in NMOSD over the last couple of years, there are now more treatment options in addition to the already existing off-label therapies. We at SRNA have therefore developed additional online resources to help you learn more about aspects of NMOSD care and therapeutics in relation to these new advancements that can significantly impact quality of life.

We have launched a brand-new NMOSD resource pack that includes:

  • An “NMOSD Therapeutics at a Glance Tool” that gives information through questions and answers on all three FDA-approved drugs and the three off-label medications that are widely used. The information includes side effects, trial results and efficacy, the safety profile, the mechanism of action, and mode of therapeutic intervention for all six drugs and more.
  • An “NMOSD Medications Page” that has this information in another format, as well as specific pages for all six drugs.


Mycophenolate Mofetil





We hope these resources will help you learn more about all NMOSD therapies and, with this knowledge, you will be better able to advocate for your care. Please reach out if you have any questions!